BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 30642444)

  • 1. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
    Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing a histology-specific biologically effective dose threshold for lung stereotactic ablative radiotherapy (SABR): Is ≥100 Gy
    Abel S; Hasan S; Verma V; Weksler B; Colonias A; Horne ZD; Wegner RE
    Lung Cancer; 2019 Sep; 135():169-174. PubMed ID: 31446991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Baine MJ; Verma V; Schonewolf CA; Lin C; Simone CB
    Lung Cancer; 2018 Apr; 118():20-26. PubMed ID: 29571997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse.
    Loganadane G; Martinetti F; Mercier O; Krhili S; Riet FG; Mbagui R; To H; Le Péchoux C; Levy A
    Cancer Treat Rev; 2016 Nov; 50():240-246. PubMed ID: 27768919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
    Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy.
    Hörner-Rieber J; Bernhardt D; Dern J; König L; Adeberg S; Paul A; Heussel CP; Kappes J; Hoffmann H; Herth FJP; Debus J; Warth A; Rieken S
    Radiother Oncol; 2017 Nov; 125(2):317-324. PubMed ID: 28919006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
    Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
    Phillips I; Sandhu S; Lüchtenborg M; Harden S
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
    Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
    Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
    JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer.
    Holgersson G; Bergström S; Bergqvist M; Nyman J; Hoye E; Helsing M; Friesland S; Holgersson M; Birath E; Ekman S; Blystad T; Ewers SB; Mörth C; Löden B; Henriksson R
    Eur J Cancer; 2011 Nov; 47(16):2415-21. PubMed ID: 21726999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
    de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
    Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
    Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.
    Harris JP; Nwachukwu C; Qian Y; Pollom E; Loo BW; Das M; Diehn M
    Lung Cancer; 2018 Oct; 124():76-85. PubMed ID: 30268484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
    Ager BJ; Wells SM; Gruhl JD; Stoddard GJ; Tao R; Kokeny KE; Hitchcock YJ
    Lung Cancer; 2019 Dec; 138():6-12. PubMed ID: 31593894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
    Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
    Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.
    Jacobs CD; Gao J; Wang X; Clarke JM; Tong B; Ready NE; Suneja G; Kelsey CR; Torok JA
    Clin Lung Cancer; 2020 May; 21(3):238-246. PubMed ID: 31757764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.